英国生物银行中他汀类药物使用与眼压、青光眼及光学相干断层扫描参数的关系
这项横断面研究纳入英国生物银行118153名有他汀使用与角膜补偿眼压数据的参与者及192283名有青光眼状态数据者(8982例病例),采用多变量校正回归分析他汀使用与眼压、黄斑视网膜神经纤维层厚度、黄斑神经节细胞内丛状层厚度及青光眼状态的关联。结果显示校正关键混杂因素后,他汀使用与眼压无差异、与青光眼患病无关联,仅与黄斑视网膜神经纤维层稍薄呈弱关联,孟德尔随机化未提示他汀降胆固醇效应对青光眼特征有因果关联。
要点
- 多变量校正后,他汀使用者与未使用者的眼压差异为0.05 mmHg(95%CI -0.02至0.13,P=0.17)。
- 他汀使用与青光眼患病无关联(OR=1.05,95%CI 0.98至1.13)。
- 他汀使用与黄斑视网膜神经纤维层稍薄呈弱关联(差异-0.15微米,95%CI -0.28至-0.01,P=0.03)。
核心结论
- 校正关键混杂因素后,未发现他汀使用与青光眼或相关特征之间存在保护性关联的证据。
研究设计与样本
- 横断面研究,纳入118153名有他汀使用和角膜补偿眼压数据的英国生物银行参与者。
- 纳入192283名有青光眼状态数据的参与者,其中8982例为青光眼病例。
- 排除神经退行性疾病参与者后,41638名有黄斑视网膜神经纤维层厚度数据、41547名有黄斑神经节细胞内丛状层厚度数据者纳入分析。
- 采用多变量校正回归模型分析他汀使用与眼压、黄斑视网膜神经纤维层厚度、黄斑神经节细胞内丛状层厚度及青光眼状态的关联,并评估青光眼多基因风险评分是否修饰关联,另进行孟德尔随机化实验。
主要发现
- 他汀使用者未校正平均眼压±标准差高于未使用者,但多变量校正模型中眼压不因他汀使用而不同(差异=0.05 mmHg,95%CI -0.02至0.13,P=0.17)。
- 他汀使用与青光眼患病无关联(OR=1.05,95%CI 0.98至1.13)。
- 他汀使用与黄斑视网膜神经纤维层较薄呈弱关联(差异=-0.15微米,95%CI -0.28至-0.01,P=0.03),但与黄斑神经节细胞内丛状层厚度无关(差异=-0.12微米,95%CI -0.29至0.05,P=0.17)。
- 青光眼多基因风险评分未修饰任何关联(交互作用P≥0.16)。
- 孟德尔随机化实验未显示他汀降胆固醇效应与多种青光眼特征之间存在因果关联的证据(逆方差加权P≥0.14)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to evaluate the relationship between statin use and glaucoma-related traits. METHODS: In a cross-sectional study, we included 118,153 UK Biobank participants with data on statin use and corneal-compensated IOP. In addition, we included 192,283 participants (8982 cases) with data on glaucoma status. After excluding participants with neurodegenerative diseases, 41,638 participants with macular retinal nerve fiber layer thickness (mRNFL) and 41,547 participants with macular ganglion cell inner plexiform layer thickness (mGCIPL) were available for analysis. We examined associations of statin use with IOP, mRNFL, mGCIPL, and glaucoma status utilizing multivariable-adjusted regression models. We assessed whether a glaucoma polygenic risk score (PRS) modified associations. We performed Mendelian randomization (MR) experiments to investigate associations with various glaucoma-related outcomes. RESULTS: Statin users had higher unadjusted mean IOP ± SD than nonusers, but in a multivariable-adjusted model, IOP did not differ by statin use (difference = 0.05 mm Hg, 95% confidence interval [CI] = -0.02 to 0.13, P = 0.17). Similarly, statin use was not associated with prevalent glaucoma (odds ratio [OR] = 1.05, 95% CI = 0.98 to 1.13). Statin use was weakly associated with thinner mRNFL (difference = -0.15 microns, 95% CI = -0.28 to -0.01, P = 0.03) but not with mGCIPL thickness (difference = -0.12 microns, 95% CI = -0.29 to 0.05, P = 0.17). No association was modified by the glaucoma PRS (Pinteraction≥ 0.16). MR experiments showed no evidence for a causal association between the cholesterol-altering effect of statins and several glaucoma traits (inverse weighted variance P ≥ 0.14). CONCLUSIONS: We found no evidence of a protective association between statin use and glaucoma or related traits after adjusting for key confounders.
引用
- Kim J, Kennedy Neary MT, Aschard H, et al. Statin Use in Relation to Intraocular Pressure, Glaucoma, and Ocular Coherence Tomography Parameters in the UK Biobank. Invest Ophthalmol Vis Sci. 2022. PMID: 35612836. doi:10.1167/iovs.63.5.31
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。